Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the directors' interests in the Ordinary shares and American Depository Shares (ADSs) of GlaxoSmithKline plc.
On 30 June 2009, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary shares at a price of £10.72 per Ordinary share and $35.54 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2009 to 30 June 2009 following this allocation, their total allocations are shown below:
Non Executive Director |
Ordinary Shares |
American Depository Shares (ADSs) |
Sir Christopher Gent |
43,462.43 |
|
Prof. Sir Roy Anderson |
4,375.53 |
|
Dr Stephanie Burns |
|
4,337.90 |
Mr Lawrence Culp |
|
15,537.94 |
Sir Crispin Davis |
33,257.85 |
|
Sir Deryck Maughan |
|
14,339.19 |
Mr James Murdoch |
201.82 |
|
Dr Daniel Podolsky |
|
6,847.75 |
Mr Tom de Swaan |
7,052.40 |
|
Sir Robert Wilson |
8,963.43 |
|
The Company and the Non-Executive Directors were informed of these allocations on 1 July 2009.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
S M Bicknell
Company Secretary
1 July 2009